Lexicon Historical Cash Flow
| LXRX Stock | USD 0.79 0.01 0.76% |
Analysis of Lexicon Pharmaceuticals cash flow over time is an excellent tool to project Lexicon Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 446.5 K or Total Cash From Financing Activities of 197.4 M as it is a great indicator of Lexicon Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Lexicon Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lexicon Pharmaceuticals is a good buy for the upcoming year.
Lexicon |
About Lexicon Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Lexicon balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Lexicon's non-liquid assets can be easily converted into cash.
Lexicon Pharmaceuticals Cash Flow Chart
Add Fundamental
Depreciation
Depreciation indicates how much of Lexicon Pharmaceuticals value has been used up. For tax purposes Lexicon Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Lexicon Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Lexicon Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lexicon Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Lexicon Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Lexicon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.At this time, Lexicon Pharmaceuticals' Change In Working Capital is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 66.6 M in 2024, despite the fact that Change In Cash is likely to grow to (22.7 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 1.2M | 1.3M | 470K | 446.5K | Depreciation | 292K | 427K | 554K | 526.3K |
Lexicon Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Lexicon Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lexicon Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (44.3M) | 90.2M | (62.2M) | (17.7M) | (23.9M) | (22.7M) | |
| Free Cash Flow | 113.7M | (143.1M) | (88.2M) | (90.2M) | (162.4M) | (154.2M) | |
| Change In Working Capital | (58.3M) | 31.1M | (10.2M) | 402K | 2.7M | 2.8M | |
| Begin Period Cash Flow | 80.4M | 36.1M | 126.3M | 64.1M | 46.3M | 66.6M | |
| Other Cashflows From Financing Activities | (2.2M) | 216.6M | 11.7M | (71.1M) | (49.9M) | (47.4M) | |
| Depreciation | 3.7M | 2.9M | 292K | 427K | 554K | 526.3K | |
| Capital Expenditures | 70K | 87K | 1.2M | 1.3M | 470K | 446.5K | |
| Total Cash From Operating Activities | 113.8M | (143.0M) | (87.0M) | (88.9M) | (161.9M) | (153.8M) | |
| Net Income | 130.1M | (58.6M) | (87.8M) | (101.9M) | (177.1M) | (168.3M) | |
| Total Cash From Financing Activities | (2.2M) | (147.6M) | 22.7M | 142.2M | 188.0M | 197.4M | |
| End Period Cash Flow | 36.1M | 126.3M | 64.1M | 46.3M | 22.5M | 21.3M | |
| Other Non Cash Items | 30.1M | (131.6M) | 54K | 744K | (2.3M) | (2.4M) | |
| Change To Account Receivables | (50.6M) | 53.2M | 381K | (14K) | (982K) | (932.9K) | |
| Change To Liabilities | (5.9M) | (21.0M) | (14.2M) | 76K | 68.4K | 65.0K | |
| Total Cashflows From Investing Activities | (155.9M) | 380.8M | 2.1M | (71.1M) | (81.7M) | (77.7M) | |
| Stock Based Compensation | 14.2M | 13.3M | 10.6M | 11.5M | 14.3M | 9.7M | |
| Sale Purchase Of Stock | (941K) | (1.0M) | (2.7M) | (864K) | (824K) | (782.8K) | |
| Change To Inventory | (2.7M) | 437K | 345K | (172K) | (381K) | (400.1K) | |
| Investments | (155.8M) | 209.4M | 3.3M | (69.8M) | (77.7M) | (73.8M) | |
| Change Receivables | (50.6M) | 53.2M | 381K | (14K) | (16.1K) | (16.9K) | |
| Net Borrowings | (1.3M) | (216.6M) | (11.7M) | 48.9M | 44.0M | 46.2M | |
| Cash And Cash Equivalents Changes | (44.3M) | 90.2M | (62.2M) | (17.7M) | (15.9M) | (15.2M) | |
| Cash Flows Other Operating | (2.2M) | (1.5M) | 3.5M | 340K | 391K | 410.6K | |
| Other Cashflows From Investing Activities | 50.8M | 169.7M | (155.8M) | 171.4M | 197.1M | 207.0M | |
| Change To Netincome | 8.2M | 12.6M | 10.6M | 11.5M | 10.4M | 8.8M | |
| Change To Operating Activities | (2.2M) | (1.5M) | 3.5M | 340K | 391K | 224.3K | |
| Issuance Of Capital Stock | 0.0 | 70.0M | 37.1M | 94.2M | 138.8M | 145.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.